Research reference
PE-22-28
A source-linked reference on PE 22-28 in cell and mouse experiments. Sources checked 6 September 2026.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
Identity
PE 22-28 is identified in this primary paper as a seven-amino-acid analogue designed from spadin degradation products. The cited paper, rather than a marketplace label, is the basis for this identity description.
Sources: PubMed, National Library of Medicine
Research context
The authors tested channel activity in hTREK-1/HEK cells and examined behavioural, neurogenesis and synaptogenesis measures in mice. These are preclinical experiments.
Sources: PubMed, National Library of Medicine
Evidence boundary
The reported antidepressant-like measures in mice do not demonstrate treatment of depression or any other condition in people. No personal-use, safety or product-quality conclusion follows from this study.
Sources: PubMed, National Library of Medicine
This source-linked record does not establish a diagnosis, treatment effect, product quality, or personal suitability.
Channel and mouse behavioural findings can guide further research, but they do not establish whether the compound reaches the relevant human tissue or has an acceptable risk profile.
Published sources
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
PubMed, National Library of Medicine. Published 2017; accessed 6 September 2026.
Supports: The study identifies PE 22-28 as a seven-amino-acid spadin analogue and reports cell and mouse experiments.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.